JIR
TBPH icon

James Investment Research’s Theravance Biopharma TBPH Stock Holding History

James Investment Research’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$252K Hold
14,833
– – 0.03% 325
2026
Q1 		$241K Hold
14,833
– – 0.03% 314
2025
Q4 		$278K Buy
+14,833
New +$246K 0.03% 309

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

James Investment Research's TBPH Position: Q2 2026 in Review

James Investment Research held its Theravance Biopharma (TBPH) position steady in Q2 2026 at 14,833 shares worth $252K. The position accounts for 0.03% of the portfolio, ranked #325.

James Investment Research first reported a position in TBPH in Q4 2025 and has held it in 3 quarters since. The position peaked at $278K in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • James Investment Research held 14,833 shares of Theravance Biopharma worth $252K as of Q2 2026.
  • James Investment Research left its Theravance Biopharma share count unchanged in Q2 2026.
  • Theravance Biopharma made up 0.03% of James Investment Research's portfolio in Q2 2026, its #325 holding.
  • James Investment Research first reported a position in Theravance Biopharma in Q4 2025 and has held it in 3 quarters since.
  • James Investment Research's Theravance Biopharma position peaked at $278K in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.